NRX Pharmaceuticals Ownership
| NRXP Stock | USD 2.08 0.01 0.48% |
NRX |
NRX Stock Ownership Analysis
About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 2.36. NRX Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of April 2024. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about NRX Pharmaceuticals contact Stephen Esq at 484 254 6134 or learn more at https://www.nrxpharma.com.NRX Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NRX Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NRX Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NRX Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NRX Pharmaceuticals Outstanding Bonds
NRX Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NRX Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NRX bonds can be classified according to their maturity, which is the date when NRX Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US62947QBB32 Corp BondUS62947QBB32 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US62944TAF21 Corp BondUS62944TAF21 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.